Skip to content

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06417710
Acronym
NANO-LM
Enrollment
200
Registered
2024-05-16
Start date
2022-01-30
Completion date
2026-12-31
Last updated
2024-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Leptomeningeal Cancer

Brief summary

The goal of this project is to develop and validate a reproducible scorecard for the neurological assessment of patients with leptomeningeal metastases that can be used in clinical trials including such patients, as well as in clinical practice.

Interventions

Clinical neurological assessment performed by 2 raters

Sponsors

M.D. Anderson Cancer Center
CollaboratorOTHER
The Netherlands Cancer Institute
CollaboratorOTHER
University of Zurich
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (18 years or more), female or male * Histologically confirmed diagnosis of extra-CNS primary solid cancer * Diagnosis of leptomeningeal metastases confirmed or probable per EANO ESMO criteria * Performance status compatible with enrolment into clinical trials * Ability to consent * Signed informed consent form from patient * Participation in a parallel clinical trial is allowed in this non-interventional study

Exclusion criteria

* Inability to give informed consent * Inability to adhere to recommended follow-up according to the treating physician Vulnerable participants will not be included.

Design outcomes

Primary

MeasureTime frame
inter-observer agreement of response assessment of the overall clinical assessment - per center and among all ratersDecember 2026

Secondary

MeasureTime frame
inter-observer reproducibility (agreement) for each item - per center and among all ratersDecember 2026
association between itemsDecember 2026
variability of the interobserver agreementDecember 2026
description of clinical neurological symptoms and signsDecember 2026
association of clinical response with imaging and CSF cytology response and the overall global clinical/MRI/CSF responseDecember 2026

Countries

Netherlands, Switzerland, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026